Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer in the phase\u00e2 $ 3 LIGHTHOUSE CRC trial

.Completing rate of interests.S.K.: Sell and also Other Ownership Enthusiasms: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Part: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Wellness, Bicara Therapeutics, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Healthcare, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Drugs, Lilly, Lutris, Merck, Mirati Rehabs, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Research Funding: Amgen (Inst), Array BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Stock and Other Possession Passions: Pfizer. J.P.: Job: Previously Pfizer. Sell as well as Other Ownership Stakes: Pfizer. F.C.: Consulting or Advisory Role: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Analysis Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Job: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Study Financing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Part: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or even Advisory Duty: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Investigation Financing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Drug, Sumitomo Corp., Takeda. Analysis Funding: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Job: Pfizer. Sell and Other Possession Interests: Pfizer. X.Z.: Employment: Pfizer. Assets and also Other Ownership Stakes: Pfizer. Patents, Aristocracies, Other Intellectual Property: Johns Hopkins University. P.H.: Job: Pfizer. Sell and Other Possession Interests: Pfizer. T.X.: Work: Pfizer. Sell as well as Other Ownership Interests: Pfizer. R.Y.: Consulting or Advisory Part: Collection BioPharma/Pfizer, Mirati Rehabs, Zai Laboratory, Amgen. Study Backing: Selection BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Function: Range BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapies, MSD, NeoPhore, Novartis, Ona Therapies, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Pharmaceutical, Tessa Rehab, TheraMyc. Other Connection: Amgen, Array Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Analysis UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Opposite el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Institute for Medical Education, Pfizer, PharmaMar, Physicansu00e2 $ Education Source, Sanofi-Aventis, Servier, Taiho Drug.